QuanterixNASDAQ: QTRX

The average price target suggests a potential increase of 67.7% for Quanterix (QTRX). Although studies show that this metric may not always be reliable, an increase in earnings estimates could indicate a positive outlook for the stock in the short term.

Quanterix's (QTRX) blood-based biomarker test offers a non-invasive alternative, potentially revolutionizing how AD is diagnosed and managed.

Quanterix Corporation (QTRX) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.50 per share a year ago.

Quanterix's (QTRX) blood-based biomarker testing offers a superior alternative, aligning with the recommendations of the NIA-AA criteria for AD diagnosis.

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX) today announced that it has rescheduled the release of its financial results for the fourth quarter and year ended December 31, 2023 and the associated conference call in order to more closely align the release of such results with the filing of its Annual Report on Form 10-K for the year ended December 31, 2023, the deadline for which is February 29, 2024. The investor call will now be held on Thursday, February 29, 2024.

Does Quanterix Corporation (QTRX) have what it takes to be a top stock pick for momentum investors? Let's find out.

The mean of analysts' price targets for Quanterix Corporation (QTRX) points to a 54.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Quanterix Corporation (NASDAQ:QTRX ) Q3 2023 Earnings Conference Call November 7, 2023 8:30 AM ET Company Participants Ed Joyce - VP, IR Masoud Toloue - President and CEO Vandana Sriram - CFO Conference Call Participants Kyle Mikson - Canaccord Genuity Jake Allen - Goldman Sachs Dan Brennan - Cowen Puneet Souda - Leerink Partners Operator Good day and thank you for standing by. Welcome to the Quanterix Corporation Q3 2023 Earnings Call.

Today, we revisit Quanterix Corporation, a life sciences company that develops and markets digital immunoassay platforms. The company has posted much better than expected quarterly numbers over the past two quarters, and third quarter numbers will be out shortly. The company has a rock-solid balance sheet, has seen some recent insider buying and just made Goldman Sach's "Conviction List."